Elsevier

The Lancet

Volume 324, Issue 8411, 10 November 1984, Pages 1055-1058
The Lancet

HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE

https://doi.org/10.1016/S0140-6736(84)91504-6Get rights and content

Abstract

The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional treatment for Kawasaki disease. Patients were allocated at random to aspirin (45 cases) or IVGG (40 cases), there being no significant intergroup differences in age, sex ratio, duration of disease until the start of treatment, or severity. The development of coronary artery dilatation was monitored by two-dimensional echocardiography. Within 29 days of the onset of the disease, this lesion had developed in 19 cases (42%) in the aspirin group and in 6 cases (15%) in the IVGG group. There were no new instances of this lesion: in the period 30-60 days coronary artery dilatation persisted in 14 and 3 cases, respectively. In patients found to have echocardiographic abnormalities selective coronary arteriography was done 30-60 days after onset of Kawasaki disease and the lesion was confirmed in 1 of the 6 cases in the IVGG group and in 11 of the 19 controls. High-dose IVGG seems to reduce the frequency of coronary artery abnormalities in patients with Kawasaki disease.

References (2)

There are more references available in the full text version of this article.

Cited by (629)

  • Adult and childhood vasculitis

    2023, Handbook of Clinical Neurology
  • Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study

    2022, Journal of Cardiology
    Citation Excerpt :

    However, CAA can be prevented by suppressing inflammation early in acute phase treatment. Initiation of intravenous immunoglobulin (IVIG) (2 g/kg) within 10 days of fever onset has been confirmed to reduce the risk of CAA by approximately 20% (from 25% to <5%) [4–8]. High-dose IVIG (2 g/kg) or combination with steroid therapy as 1st line treatment has reduced rates of cardiac sequelae in Japan [9].

View all citing articles on Scopus
View full text